Search
Now showing items 1-6 of 6
The design and evaluation of an l-dopa-lazabemide prodrug for the treatment of Parkinson’s disease
(MDPI, 2017)
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and ...
The monoamine oxidase inhibition properties of selected structural analogues of methylene blue
(Elsevier, 2017)
The thionine dye, methylene blue (MB), is a potent inhibitor of monoamine oxidase (MAO) A, a property that may, at least in part, mediate its antidepressant effects in humans and animals. The central inhibition of MAO-A ...
Inhibition of c-steel corrosion by green tea extract in hydrochloric solution
(ESG, 2017)
Inhibition ability of green tea extract (GTE) on the C38 steel (CS) in 1.0 M HCl was evaluated using different methods such as: weight loss, electrochemical impedance spectroscopy (EIS) and potentiodynamic polarization ...
Corticospinal responses following strength training: a systematic review and meta‐analysis
(Wiley, 2017)
Strength training results in changes in skeletal muscle; however, changes in the central nervous system also occur. Over the last 15 years, non‐invasive brain stimulation techniques, such as transcranial magnetic stimulation, ...
Benzyloxynitrostyrene analogues: a novel class of selective and highly potent inhibitors of monoamine oxidase B
(Elsevier, 2017)
This study examines a series of novel 3-benzyloxy-β-nitrostyrene analogues as a novel class of inhibitors of the monoamine oxidase (MAO) enzymes. MAO inhibitors are considered useful for the treatment of depression and ...
The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase
(Elsevier, 2017)
The monoamine oxidase (MAO) enzymes are of considerable pharmacological interest and inhibitors are used in the clinic for the treatment of major depressive disorder and Parkinson's disease. A limited number of studies ...